Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(2):400–404. doi: 10.1111/j.1476-5381.1995.tb13240.x

Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein.

E S Ellis 1, C Byrne 1, O E Murphy 1, N S Tilford 1, G S Baxter 1
PMCID: PMC1510266  PMID: 7881740

Abstract

1. An 'atypical' 5-HT2 receptor which is located on the endothelium of rat jugular vein has been described. In the present study we have further defined the nature of the 5-HT2 receptor subtype present in this preparation. 2. In experiments conducted in the presence of ketanserin to preclude involvement of 5-HT2 receptors, the mixed 5-HT2B/2C antagonist, SB 200646, acted as an antagonist of 5-HT at the endothelial 5-HT receptor (pA2 = 7.2). Yohimbine, which exhibits negligible affinity for rat 5-HT2C receptors but has high 5-HT2B receptor affinity, acted as a potent but non-surmountable antagonist (pA2 > or = 7.3) in rat jugular vein. Neither yohimbine nor SB 200646 affected endothelium-dependent relaxations induced by carbachol. 3. Mianserin also acted as a surmountable antagonist (pA2 = 7.3) and the 5-HT2B agonist, BW 723C86, acted as a potent partial agonist (pEC50 [95% C L], intrinsic activity +/- s.e. mean = 7.9 [7.6-8.3], 0.84 +/- 0.04). Responses to BW 723C86 were antagonized by SB 200646 (0.3 microM) yielding an 'apparent' pA2 [95% CL] of 7.03 [6.76-7.32]. 4. These data are consistent with the presence of 5-HT2B receptors mediating endothelium-dependent relaxation of rat jugular vein.

Full text

PDF
400

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baxter G. S., Murphy O. E., Blackburn T. P. Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol. 1994 May;112(1):323–331. doi: 10.1111/j.1476-5381.1994.tb13072.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bodelsson M., Törnebrandt K., Arneklo-Nobin B. Endothelial relaxing 5-hydroxytryptamine receptors in the rat jugular vein: similarity with the 5-hydroxytryptamine1C receptor. J Pharmacol Exp Ther. 1993 Feb;264(2):709–716. [PubMed] [Google Scholar]
  4. Clineschmidt B. V., Reiss D. R., Pettibone D. J., Robinson J. L. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. J Pharmacol Exp Ther. 1985 Dec;235(3):696–708. [PubMed] [Google Scholar]
  5. Forbes I. T., Kennett G. A., Gadre A., Ham P., Hayward C. J., Martin R. T., Thompson M., Wood M. D., Baxter G. S., Glen A. N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J Med Chem. 1993 Apr 16;36(8):1104–1107. doi: 10.1021/jm00060a019. [DOI] [PubMed] [Google Scholar]
  6. Frankhuyzen A. L., Bonta I. L. Effect of mianserin, a potent anti-serotonin agent, on the isolated rat stomach fundus preparation. Eur J Pharmacol. 1974 Jan;25(1):40–50. doi: 10.1016/0014-2999(74)90092-2. [DOI] [PubMed] [Google Scholar]
  7. Gardiner S. M., Kemp P. A., March J. E., Bennett T., Davenport A. P., Edvinsson L. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol. 1994 Jun;112(2):477–486. doi: 10.1111/j.1476-5381.1994.tb13098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gupta P. An endothelial 5-HT receptor that mediates relaxation in guinea-pig isolated jugular vein resembles the 5-HT1D subtype. Br J Pharmacol. 1992 Jul;106(3):703–709. doi: 10.1111/j.1476-5381.1992.tb14398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoyer D., Waeber C., Schoeffter P., Palacios J. M., Dravid A. 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization. Naunyn Schmiedebergs Arch Pharmacol. 1989 Mar;339(3):252–258. doi: 10.1007/BF00173573. [DOI] [PubMed] [Google Scholar]
  10. Leff P., Martin G. R., Morse J. M. Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogues. Br J Pharmacol. 1987 Jun;91(2):321–331. doi: 10.1111/j.1476-5381.1987.tb10287.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Loric S., Launay J. M., Colas J. F., Maroteaux L. New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett. 1992 Nov 9;312(2-3):203–207. doi: 10.1016/0014-5793(92)80936-b. [DOI] [PubMed] [Google Scholar]
  12. Schoeffter P., Hoyer D. 5-Hydroxytryptamine (5-HT)-induced endothelium-dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 5-HT1D receptor subtype. J Pharmacol Exp Ther. 1990 Jan;252(1):387–395. [PubMed] [Google Scholar]
  13. Sumner M. J. Characterization of the 5-HT receptor mediating endothelium-dependent relaxation in porcine vena cava. Br J Pharmacol. 1991 Apr;102(4):938–942. doi: 10.1111/j.1476-5381.1991.tb12280.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Van Nueten J. M., Janssen P. A., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. 1981 Jul;218(1):217–230. [PubMed] [Google Scholar]
  15. Wainscott D. B., Cohen M. L., Schenck K. W., Audia J. E., Nissen J. S., Baez M., Kursar J. D., Lucaites V. L., Nelson D. L. Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419–426. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES